-
1.
公开(公告)号:US20130059807A1
公开(公告)日:2013-03-07
申请号:US13402819
申请日:2012-02-22
IPC分类号: A61K31/554 , A61K31/38 , A61K31/575 , A61K31/506 , A61K31/56 , A61K31/4453 , A61K31/454 , A61K31/40 , A61K31/495 , A61K31/5377 , A61K31/155 , A61K31/4995 , A61K31/7048 , A61P1/04 , A61P3/10 , A61P3/04 , A61P29/00 , A61K31/439
CPC分类号: A61K31/496 , A61K9/0031 , A61K9/02 , A61K9/286 , A61K31/155 , A61K31/16 , A61K31/18 , A61K31/19 , A61K31/191 , A61K31/216 , A61K31/38 , A61K31/40 , A61K31/42 , A61K31/452 , A61K31/454 , A61K31/495 , A61K31/4985 , A61K31/4995 , A61K31/513 , A61K31/5377 , A61K31/55 , A61K31/554 , A61K31/575 , A61K31/655 , A61K31/7042 , A61K45/06 , C07C279/14 , C07D295/13 , C07D401/12 , A61K2300/00
摘要: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
-
公开(公告)号:US20130034536A1
公开(公告)日:2013-02-07
申请号:US13566898
申请日:2012-08-03
申请人: Bronislava GEDULIN
发明人: Bronislava GEDULIN
IPC分类号: A61K31/554 , A61K31/155 , A61K38/02 , A61K31/38 , A61K31/4985 , A61K31/4436 , A61K31/7042 , A61K31/7052 , A61K31/56 , A61K31/57 , A61K31/575 , A61K31/506 , A61K31/42 , A61K31/55 , A61K31/167 , A61P1/18 , A61P29/00 , A61K38/48
CPC分类号: A61K31/155 , A61K31/55 , A61K31/554 , A61K31/575 , A61K31/58 , A61K38/09 , A61K38/26 , A61K45/06 , A61K2300/00
摘要: Provided herein are methods and compositions comprising bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists for the treatment of pancreatitis or prevention of pancreatitis.
摘要翻译: 本文提供了包含胆汁酸转运抑制剂和/或肠内分泌肽增强剂和/或用于治疗胰腺炎或预防胰腺炎的FXR激动剂的方法和组合物。
-
公开(公告)号:US20130023470A1
公开(公告)日:2013-01-24
申请号:US13618922
申请日:2012-09-14
CPC分类号: A61K9/0019 , A61K38/00 , A61K38/22 , A61K38/2207 , A61K38/2264 , A61K38/23 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/44 , C07K14/57563 , Y10S514/866 , A61K2300/00
摘要: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译: 公开了通过减少食物摄入可以缓解的病症或病症的方法,其包括单独施用有效量的毒蜥外泌肽或毒蜥外泌肽激素,或与影响饱腹感的其它化合物或组合物联合施用。 该方法可用于治疗条件或障碍,包括肥胖,II型糖尿病,进食障碍和胰岛素抵抗综合征。 该方法对于降低血浆葡萄糖水平,降低血浆脂质水平,降低心脏风险,降低食欲和降低受试者的体重也是有用的。 还公开了用于本发明方法的药物组合物。
-
4.
公开(公告)号:US09339480B2
公开(公告)日:2016-05-17
申请号:US12623977
申请日:2009-11-23
IPC分类号: A01N43/00 , A61K31/33 , A01N43/40 , A61K31/445 , A61K31/155 , A61K31/16 , A61K31/40 , A61K31/452 , A61K31/454 , A61K31/495 , A61K31/5377 , A61K31/554
CPC分类号: A61K31/5377 , A61K9/0053 , A61K9/4808 , A61K9/4825 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K31/155 , A61K31/16 , A61K31/40 , A61K31/452 , A61K31/454 , A61K31/495 , A61K31/4985 , A61K31/4995 , A61K31/554
摘要: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.
摘要翻译: 本文提供了利用胆汁酸转运抑制剂治疗肥胖和糖尿病的方法。
-
公开(公告)号:US20120295850A1
公开(公告)日:2012-11-22
申请号:US13567932
申请日:2012-08-06
CPC分类号: A61K38/26
摘要: The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
摘要翻译: 本公开提供了使用GLP-1受体激动剂化合物来治疗患者的胰腺炎(例如急性,慢性,出血性,坏死性)。 本公开还提供了GLP-1受体激动剂化合物在患者体内降低升高的血浆淀粉酶和/或脂肪酶浓度的用途。 示例性的GLP-1受体激动剂化合物是艾塞那肽。
-
公开(公告)号:US20110306549A1
公开(公告)日:2011-12-15
申请号:US13155211
申请日:2011-06-07
CPC分类号: A61K38/26
摘要: The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
摘要翻译: 本公开提供了GLP-1受体激动剂化合物用于治疗患者中的胰腺炎(例如急性,慢性,出血性,坏死性)的用途。 本公开还提供了GLP-1受体激动剂化合物在患者体内降低升高的血浆淀粉酶和/或脂肪酶浓度的用途。 示例性的GLP-1受体激动剂化合物是艾塞那肽。
-
公开(公告)号:US20070037750A1
公开(公告)日:2007-02-15
申请号:US11584114
申请日:2006-10-19
申请人: Andrew Young , Bronislava Gedulin
发明人: Andrew Young , Bronislava Gedulin
IPC分类号: A61K38/22
CPC分类号: C07K14/57563 , A61K38/00 , A61K47/60
摘要: Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provided. These methods are are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucgon or suppressing glucagon secretion.
摘要翻译: 使用与一种或多种聚乙二醇聚合物连接的毒蜥外泌肽或毒蜥外泌激素,例如降低胰高血糖素水平和/或抑制受试者中胰高血糖素分泌的毒蜥外泌肽,毒蜥外泌肽激动剂或经修饰的毒蜥外泌肽或毒蜥外泌肽激素的方法是: 提供。 这些方法可用于治疗高胰高血糖素血症和通过降低血浆胰高血糖素或抑制胰高血糖素分泌而受益的其它病症。
-
公开(公告)号:US20050215469A1
公开(公告)日:2005-09-29
申请号:US10894999
申请日:2004-07-19
IPC分类号: A61K45/00 , A61K35/56 , A61K38/00 , A61K38/17 , A61K38/22 , A61K38/23 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/00 , C07K14/575
CPC分类号: A61K9/0019 , A61K38/00 , A61K38/22 , A61K38/2207 , A61K38/2264 , A61K38/23 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/44 , C07K14/57563 , Y10S514/866 , A61K2300/00
摘要: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译: 公开了通过减少食物摄入可以缓解的病症或病症的方法,其包括单独施用有效量的毒蜥外泌肽或毒蜥外泌肽激素,或与影响饱腹感的其它化合物或组合物联合施用。 该方法可用于治疗条件或障碍,包括肥胖,II型糖尿病,进食障碍和胰岛素抵抗综合征。 该方法对于降低血浆葡萄糖水平,降低血浆脂质水平,降低心脏风险,降低食欲和降低受试者的体重也是有用的。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号:US06858576B1
公开(公告)日:2005-02-22
申请号:US08908867
申请日:1997-08-08
IPC分类号: A61K45/00 , A61K38/00 , A61K38/22 , A61P1/00 , A61P1/06 , C07K7/02 , C07K14/575 , A61K38/16 , A61K38/17 , A61K38/26 , C07K5/00
CPC分类号: C07K14/605 , A61K38/00 , A61K38/22 , A61K38/26 , C07K14/57563 , A61K2300/00
摘要: Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
摘要翻译: 公开了减少胃动力和延迟胃排空用于治疗和诊断目的的方法,其包括施用有效量的毒蜥外泌肽或毒蜥外泌肽激动剂。 公开了治疗与升高的,不适当的或不期望的餐后血糖水平相关的病症的方法,其包括单独施用有效量的毒蜥外泌肽或毒蜥外泌肽激素,或与其他抗胃排空剂联合施用。
-
公开(公告)号:US10188646B2
公开(公告)日:2019-01-29
申请号:US13402819
申请日:2012-02-22
IPC分类号: A61K31/575 , A61K31/496 , A61K9/00 , A61K9/02 , A61K9/28 , A61K31/155 , A61K31/16 , A61K31/18 , A61K31/19 , A61K31/191 , A61K31/216 , A61K31/38 , A61K31/40 , A61K31/42 , A61K31/452 , A61K31/454 , A61K31/495 , A61K31/4985 , A61K31/4995 , A61K31/513 , A61K31/5377 , A61K31/55 , A61K31/554 , A61K31/655 , A61K31/7042 , A61K45/06 , C07C279/14 , C07D295/13 , C07D401/12 , C07D487/08
摘要: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
-
-
-
-
-
-
-
-
-